These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 27404705)

  • 41. In-scaffold restenosis in a previous left main bifurcation lesion treated with bioresorbable scaffold v-stenting.
    Miyazaki T; Panoulas VF; Sato K; Kawamoto H; Naganuma T; Latib A; Colombo A
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):e7-e10. PubMed ID: 25499306
    [No Abstract]   [Full Text] [Related]  

  • 42. Optical Coherence Tomography- Versus Angiography-Guided Magnesium Bioresorbable Scaffold Implantation in NSTEMI Patients.
    Fallesen CO; Antonsen L; Maehara A; Noori M; Hougaard M; Hansen KN; Ellert J; Ahlehoff O; Veien KT; Lassen JF; Junker AB; Hansen HS; Jensen LO
    Cardiovasc Revasc Med; 2022 Jul; 40():101-110. PubMed ID: 34949544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'.
    Kočka V; Malý M; Toušek P; Buděšínský T; Lisa L; Prodanov P; Jarkovský J; Widimský P
    Eur Heart J; 2014 Mar; 35(12):787-94. PubMed ID: 24419808
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Everolimus-eluting bioresorbable vascular scaffolds implanted in coronary bifurcation lesions: Impact of polymeric wide struts on side-branch impairment.
    De Paolis M; Felix C; van Ditzhuijzen N; Fam JM; Karanasos A; de Boer S; van Mieghem NM; Daemen J; Costa F; Bergoli LC; Ligthart JM; Regar E; de Jaegere PP; Zijlstra F; van Geuns RJ; Diletti R
    Int J Cardiol; 2016 Oct; 221():656-64. PubMed ID: 27423087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term invasive follow-up of bioresorbable vascular scaffold: Optical Coherence Tomography assessment of jailed side branches.
    Paradies V; Smits PC; Vachojannis GJ; Royaards KJ; Wassing J; van der Ent M
    Cardiovasc Revasc Med; 2018 Apr; 19(3 Pt A):279-285. PubMed ID: 29066339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new novolimus-eluting bioresorbable scaffold for large coronary arteries: an OCT study of acute mechanical performance.
    Boeder NF; Koepp T; Dörr O; Bauer T; Mattesini A; Elsässer A; Möllmann H; Blachutzik F; Achenbach S; Ghanem A; Hamm CW; Nef HM
    Int J Cardiol; 2016 Oct; 220():706-10. PubMed ID: 27393853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a single-centre experience.
    Floré V; Brown AJ; Giblett JP; Liou K; Cranley J; Hoole SP; West NEJ
    EuroIntervention; 2019 Apr; 14(17):1776-1783. PubMed ID: 30375333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Computed tomography angiography for guiding and follow-up of magnesium-bioresorbable scaffold implantation.
    Opolski MP; Kepka C; Wojakowski W; Witkowski A
    Clin Res Cardiol; 2019 Mar; 108(3):344-346. PubMed ID: 30182164
    [No Abstract]   [Full Text] [Related]  

  • 49. Long-term follow-up of BVS from a prospective multicenter registry: Impact of a dedicated implantation technique on clinical outcomes.
    Regazzoli D; Latib A; Ezhumalai B; Tanaka A; Leone PP; Khan S; Kumar V; Rastogi V; Ancona MB; Mangieri A; Giannini F; Mitomo S; Seth A; Colombo A
    Int J Cardiol; 2018 Nov; 270():113-117. PubMed ID: 29983253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of in-stent restenosis with bioresorbable vascular scaffolds: optical coherence tomography insights.
    Rivero F; Bastante T; Cuesta J; Benedicto A; Restrepo JA; Alfonso F
    Can J Cardiol; 2015 Mar; 31(3):255-9. PubMed ID: 25660152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optical coherence tomography in bioabsorbable stents: mechanism of vascular response and guidance of stent implantation.
    Mattesini A; Pighi M; Konstantinidis N; Ghione M; Kilic D; Foin N; Dall'ara G; Secco GG; Valente S; Di Mario C
    Minerva Cardioangiol; 2014 Feb; 62(1):71-82. PubMed ID: 24500218
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coronary calcification as a mechanism of plaque/media shrinkage in vessels treated with bioresorbable vascular scaffold: A multimodality intracoronary imaging study.
    Zeng Y; Cavalcante R; Collet C; Tenekecioglu E; Sotomi Y; Miyazaki Y; Katagiri Y; Asano T; Abdelghani M; Nie S; Bourantas CV; Bruining N; Onuma Y; Serruys PW
    Atherosclerosis; 2018 Feb; 269():6-13. PubMed ID: 29247976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implantation of bioresorbable vascular scaffolds following acute coronary syndrome is associated with reduced early neointimal growth and strut coverage.
    Giblett JP; Brown AJ; Keevil H; Jaworski C; Hoole SP; West NE
    EuroIntervention; 2016 Aug; 12(6):724-33. PubMed ID: 27542784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fracture with the newer bioresorbable vascular scaffolds.
    Elwany M; Di Palma G; Cortese B
    Catheter Cardiovasc Interv; 2017 Oct; 90(4):582-583. PubMed ID: 28295999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optical Coherence Tomography Guided Percutaneous Coronary Intervention.
    Ha FJ; Giblett JP; Nerlekar N; Cameron JD; Meredith IT; West NEJ; Brown AJ
    Heart Lung Circ; 2017 Dec; 26(12):1267-1276. PubMed ID: 28818410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of coronary bifurcation lesions with the Absorb bioresorbable vascular scaffold in combination with the Tryton dedicated coronary bifurcation stent: evaluation using two- and three-dimensional optical coherence tomography.
    Grundeken MJ; Hassell ME; Kraak RP; de Bruin DM; Koch KT; Henriques JP; van Leeuwen TG; Tijssen JG; Piek JJ; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2015 Dec; 11(8):877-84. PubMed ID: 25169592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Clinical Presentation on Early Vascular Healing After Bioresorbable Vascular Scaffold Implantation.
    Baquet M; Brenner C; Wenzler M; Eickhoff M; David J; Brunner S; Theiss H; Massberg S; Guagliumi G; Mehilli J
    J Interv Cardiol; 2017 Feb; 30(1):16-23. PubMed ID: 27896843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers.
    Robaei D; Back L; Ooi SY; Pitney M; Jepson N
    J Invasive Cardiol; 2016 Aug; 28(8):316-22. PubMed ID: 26567454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes.
    Gori T; Schulz E; Hink U; Kress M; Weiers N; Weissner M; Jabs A; Wenzel P; Capodanno D; Münzel T
    JACC Cardiovasc Interv; 2015 May; 8(6):770-777. PubMed ID: 25999097
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes.
    Kochman J; Tomaniak M; Pietrasik A; Kołtowski Ł; Rdzanek A; Huczek Z; Mazurek T; Jąkała J; Ząbek A; Legutko J; Kochman W; Filipiak KJ
    Cardiol J; 2015; 22(3):315-22. PubMed ID: 25428734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.